Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PDS Biotechnology CorpPDSB · Entity 7939 | Chief Financial Officer | January 12, 2026 | March 03, 2026 |
| Roka BioScience, Inc.ROKA · Entity 172682 | Vice President, CFO | March 24, 2017 | March 28, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PDS Biotechnology Corp
Report date January 12, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.98 · Expires 2036-01-12 | Direct | 300,000 |
Reported balance
After 2026-01-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-12 · Grant · Acquired 300,000 · Balance 300,000 F1: The option will vest over four years, as follows: 25% of the shares underlying the option will vest and become exercisable on January 12, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest over four years, as follows: 25% of the shares underlying the option will vest and become exercisable on January 12, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.
Roka BioScience, Inc.
Report date March 24, 2017 · Filed March 28, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stock, par value $0.001 per shareSEC Table II · derivative / convertible security · Conversion / exercise price $3.45 · Expires 2027-03-23 | Direct | 54,000 |
Reported balance
After 2017-03-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-03-24 · Grant · Acquired 54,000 · Balance 54,000 F1: Such stock options vest 25% on March 24, 2018 and in twelve equal increments on a quarterly basis beginning three months after that. The stock options have a term of ten years. |
Filing footnotes · ownership attribution and instrument terms
F1: Such stock options vest 25% on March 24, 2018 and in twelve equal increments on a quarterly basis beginning three months after that. The stock options have a term of ten years.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 12, 2026 Filed Mar 3, 2026 23:47 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantEmployee Stock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0001140361-26-007646 · form4.xml · derivative · entry 1 Boesgaard Lars · CIK 0001403893 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2036-01-12 F1 · derivative.exercise_date: The option will vest over four years, as follows: 25% of the shares underlying the option will vest and become exercisable on January 12, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| June 12, 2025 Filed Jul 25, 2025 22:12 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantEmployee Stock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001140361-25-027402 · form4.xml · derivative · entry 1 Boesgaard Lars · CIK 0001403893 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2035-06-12 F1 · derivative.exercise_date: The option will vest over four years, as follows: 25% of the shares underlying the option will vest and become exercisable on June 12, 2026, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| December 04, 2023 Filed Dec 4, 2023 23:14 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantEmployee Stock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $5.28 | $0.00 |
DisclosureSEC source: 0001140361-23-056240 · form4.xml · derivative · entry 1 Boesgaard Lars · CIK 0001403893 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2033-12-04 F1 · derivative.exercise_date: The option was granted by the Issuer as an inducement material to the Reporting Person entering into employment with the Issuer in accordance with Nasdaq Rule 5635(c)(4) and the Issuer's 2019 Inducement Plan, as amended. The option will vest over four years, as follows: 25% of the shares underlying the option will vest and become exercisable on December 4, 2024, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| March 24, 2017 Filed Mar 28, 2017 16:35 UTC | Roka BioScience, Inc. ROKA · Entity 172682 | GrantCommon stock, par value $0.001 per share · Derivative | 54,000 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001472343-17-000022 · wf-form4_149073329751227.xml · derivative · entry 1 Boesgaard Lars · CIK 0001403893 · Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,000 Underlying: Common Stock · 54,000 shares Expires 2027-03-23 F1 · derivative.exercise_date: Such stock options vest 25% on March 24, 2018 and in twelve equal increments on a quarterly basis beginning three months after that. The stock options have a term of ten years. Read SEC document |
| November 10, 2016 Filed Nov 10, 2016 16:16 UTC | Roka BioScience, Inc. ROKA · Entity 172682 | ConversionSeries A Convertible Preferred Stock · Derivative | 25 | $0.00 | $0.00 |
DisclosureSEC source: 0001472343-16-000238 · wf-form4_147881257960648.xml · derivative · entry 2 Boesgaard Lars · CIK 0001403893 · Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock, par value $0.001 per share · 3,572 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Reporting person's Series A Convertible Preferred Stock, par value $0.001 per share (the "Series A Preferred Shares") automatically converted into shares of the Company's common stock, par value $0.001 (the "Common Shares") at a conversion price of $7.00 per share resulting in his acquisition of 3,572 Common Shares. Common Shares disclosed reflect the October 11, 2016, 10 for 1 reverse stock split of the Company's Common Shares. The Series A Preferred Shares were adjusted proportionately and consequently, each share of Preferred Stock became convertible into approximately 143 shares of common stock. F2 · derivative.exercise_date: The Series A Preferred Shares automatically converted, upon receipt of Company shareholder approval and had no expiration date. F2 · derivative.expiration_date: The Series A Preferred Shares automatically converted, upon receipt of Company shareholder approval and had no expiration date. Read SEC document |
| November 10, 2016 Filed Nov 10, 2016 16:16 UTC | Roka BioScience, Inc. ROKA · Entity 172682 | ConversionCommon Stock, $0.001 par value per share | 3,572 | $7.00 | $25,004.00 |
DisclosureSEC source: 0001472343-16-000238 · wf-form4_147881257960648.xml · nonDerivative · entry 1 Boesgaard Lars · CIK 0001403893 · Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,938 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 16:31 UTC | Roka BioScience, Inc. ROKA · Entity 172682 | PurchaseWarrant (right to buy) · Derivative | 35,714 | Not disclosed Strike: $0.70 | Not disclosed |
DisclosureSEC source: 0001472343-16-000197 · wf-form4_147466266692520.xml · derivative · entry 2 Boesgaard Lars · CIK 0001403893 · Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,714 Underlying: Common stock, par value $0.001 per share · 35,714 shares Expires 2016-09-21 F2 · price: The reporting person purchased 25 Series A Preferred Shares and five-year warrants to purchase 35,714 Common Shares at a purchase price of $1,000 per share pursuant to a private offering of the Company for a total of $25,000. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 16:31 UTC | Roka BioScience, Inc. ROKA · Entity 172682 | PurchaseSeries A Convertible Preferred Stock · Derivative | 25 | Not disclosed Strike: $0.70 | Not disclosed |
DisclosureSEC source: 0001472343-16-000197 · wf-form4_147466266692520.xml · derivative · entry 1 Boesgaard Lars · CIK 0001403893 · Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25 Underlying: Common stock, par value $0.001 per share · 35,714 shares Expires not disclosed F2 · price: The reporting person purchased 25 Series A Preferred Shares and five-year warrants to purchase 35,714 Common Shares at a purchase price of $1,000 per share pursuant to a private offering of the Company for a total of $25,000. F1 · derivative.exercise_date: Pursuant to the terms of the Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock and the lock up agreement dated September 21, 2016, reporting person's Series A Convertible Preferred Stock, par value $0.001 per share (the "Series A Preferred Shares") automatically converts, upon receipt by the Company of shareholder approval, into shares of the Company's common stock, par value $0.001 (the "Common Shares") at a conversion price of $0.70 per share. The Series A Preferred Shares have no expiration date. F1 · derivative.expiration_date: Pursuant to the terms of the Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock and the lock up agreement dated September 21, 2016, reporting person's Series A Convertible Preferred Stock, par value $0.001 per share (the "Series A Preferred Shares") automatically converts, upon receipt by the Company of shareholder approval, into shares of the Company's common stock, par value $0.001 (the "Common Shares") at a conversion price of $0.70 per share. The Series A Preferred Shares have no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.